NCT Number |
Title |
Conditions |
Interventions |
Sponsor
Collaborators |
Phases |
NCT03338959 |
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma |
Soft Tissue Sarcoma |
Biological: Pembrolizumab|Radiation: Radiation Therapy |
Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) |
Phase 1
Phase 2 |
NCT03247712 |
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma |
Drug: Nivolumab|Procedure: Surgical Resection|Radiation: Radiation |
Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute |
Phase 1
Phase 2 |
NCT02834052 |
Pembrolizumab + Poly-ICLC in MRP Colon Cancer |
Metastatic Colon Cancer|Solid Tumor |
Drug: pembrolizumab|Drug: Poly-ICLC |
Asha Nayak|Oncovir, Inc.|Merck Sharp & Dohme Corp.|Augusta University |
Phase 1
Phase 2 |
NCT03381547 |
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010 |
Healthy Adult Subjects |
Biological: AM0010 |
ARMO BioSciences |
Phase 1 |
NCT03379493 |
Study of ET190L1-ARTEMIS??T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma |
Lymphomas Non-Hodgkin's B-Cell |
Biological: ET190L1-ARTEMIS¢â T cells |
Eureka Therapeutics Inc.|Duke University|Duke Clinical Research Institute |
Phase 1 |
NCT03364348 |
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer |
HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer |
Drug: Utomilumab|Drug: Trastuzumab|Drug: Trastuzumab Emtansine |
George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University |
Phase 1 |
NCT03338972 |
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|TNFRSF17 Positive |
Biological: BCMA-specific CAR-expressing T Lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis |
Fred Hutchinson Cancer Research Center|Juno Therapeutics, Inc.|National Cancer Institute (NCI) |
Phase 1 |
NCT03331341 |
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma |
Classical Hodgkin Lymphoma |
Drug: Dacarbazine|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Vinblastine |
University of Washington|National Cancer Institute (NCI) |
Phase 2 |
NCT03311828 |
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma |
Recurrent Plasma Cell Myeloma |
Biological: Daratumumab|Drug: Imaging Agent|Procedure: Positron Emission Tomography |
City of Hope Medical Center |
Phase 1 |
NCT03271814 |
Brain Biomarker on Inflammation Response |
Schizophrenia |
Biological: LPS|Other: Placebo |
University of Maryland |
Phase 1 |
NCT03260504 |
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer |
Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer |
Biological: Aldesleukin|Biological: Pembrolizumab |
University of Washington|National Cancer Institute (NCI) |
Phase 1 |
NCT03197025 |
Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions |
Human Papillomavirus|HPV-16|High Grade Squamous Intraepithelial Lesion |
Drug: Aldesleukin|Biological: E6 TCR |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03174275 |
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma |
Carcinoma, Squamous Cell|Oral Cancer|Oropharynx Cancer|Larynx Cancer|Lip Cancer|Esophageal Cancer |
Drug: Durvalumab|Drug: Carboplatin|Drug: Nab-paclitaxel|Drug: Cisplatin|Procedure: Surgical resection|Radiation: IMRT |
UNC Lineberger Comprehensive Cancer Center|AstraZeneca|Celgene |
Phase 2 |
NCT03377361 |
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread |
Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm |
Biological: Nivolumab|Drug: Trametinib|Biological: Ipilimumab |
Bristol-Myers Squibb|Novartis |
Phase 1
Phase 2 |